Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial - Concepedia

Concepedia

Publication | Open Access

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

DOI Full Paper Access

300

Citations

26

References

2021

Year

Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony Elias,

I-spy2 TrialBreast OncologyMedicinePharmacologyImmune Checkpoint InhibitorBreast CancerCancer TreatmentOncologyRadiation OncologyMolecular Oncology

References

	Year	Citations

Page 1

Page 1